Negative VE and rVE against severe COVID-19 outcomes

Several studies reported that COVID-19 vaccine effectiveness (VE) and relative vaccine effectiveness (rVE) against severe COVID-19 outcomes can turn negative after a few months.  

One recently published paper (data analyzed were from 8 December 2020 to 30 June 2021) concludes that For Doses 1 and 2 of ChAdOx1 and Dose 1 of BNT162b2, VE/rVE reached zero by approximately Days 60–80 and then went negative. By Day 70, VE/rVE was –25% (95% CI: –80 to 14) and 10% (95% CI: –32 to 39) for Doses 1 and 2 of ChAdOx1 (see Figure). The same trend was observed for BNT162b2 although it seemed to provide a better protection.

Another not-yet published paper found that vaccine effectiveness was waning for all studied doses, including the 4th booster that worked for 90 days. Among health-care workers who had not had previous SARS-CoV-2 infection, time-specific vaccine effectiveness decreased from 52% (95% CI, 45 to 58) during the first 5 weeks after vaccination to −2% (95% CI, −27 to 17) at 15 to 26 weeks.

Vaccine effectiveness for children was negligible or negative 3 months or more after vaccination (−1.7%; 95% CI, −16.9 to 11.5 among those who had completed their primary series between February 1, 2021, and June 30, 2021, according to this Qatar study)

According to a study from Netherlands, during the Omicron-period, vaccine effectiveness against infection (VE-infection) was -36% (95% CI: -88%-1%) for primary series and -30% (95% CI: -80%-6%) for booster vaccination. It was positive for infectiousness though - indicating that vaccinated people may be less likely to pass the virus to each other.  

Previously we discussed the Walgreens testing data that suggested waning and negative efficiency. Another previous post addressed reports from US and UK with the same conclusion. The latter study observed negative vaccine effectiveness (VE) for the third dose since December 20, 2021, with a significantly increased proportion of SARS-CoV2 cases hospitalizations, and deaths among the vaccinated; and a decreased proportion of cases, hospitalizations, and deaths among the unvaccinated. UK data included SARS-CoV2 cases reported under pillar 1 (public health laboratories and hospitals) and pillar 2 (community testing) among various age groups (0-19, 20-29, 30-49, 50-69, ≥50, ≥70 and ≥80 years of age) from September 28, 2020, to May 1, 2022.


REFERENCES

Steven Kerr, Stuart Bedston, Declan T Bradley, Mark Joy, Emily Lowthian, Rachel M Mulholland, Ashley Akbari, F D Richard Hobbs, Srinivasa Vittal Katikireddi, Simon de Lusignan, Igor Rudan, Fatemeh Torabi, Ruby S M Tsang, Ronan A Lyons, Chris Robertson, Aziz Sheikh, Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales, International Journal of Epidemiology, 2022;, dyac199, https://doi.org/10.1093/ije/dyac199

Effectiveness of mRNA-1273 against infection and COVID-19 hospitalization with SARS-CoV-2 Omicron subvariants: BA.1, BA.2, BA.2.12.1, BA.4, and BA.5 Hung Fu Tseng, Bradley K. Ackerson, Katia J. Bruxvoort, Lina S. Sy, Julia E. Tubert, Gina S. Lee, Jennifer H. Ku, Ana Florea, Yi Luo, Sijia Qiu, Soon Kyu Choi, Harpreet S. Takhar, Michael Aragones, Yamuna D. Paila, Scott Chavers, Lei Qian medRxiv 2022.09.30.22280573; doi: https://doi.org/10.1101/2022.09.30.22280573

Chemaitelly H, AlMukdad S, Ayoub HH, Altarawneh HN, Coyle P, Tang P, Yassine HM, Al-Khatib HA, Smatti MK, Hasan MR, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Al-Romaihi HE, Butt AA, Al-Thani MH, Al-Khal A, Bertollini R, Abu-Raddad LJ. Covid-19 Vaccine Protection among Children and Adolescents in Qatar. N Engl J Med. 2022 Nov 2. doi: 10.1056/NEJMoa2210058. Epub ahead of print. PMID: 36322837.

Canetti M, Barda N, Gilboa M, Indenbaum V, Asraf K, Gonen T, Weiss-Ottolenghi Y, Amit S, Doolman R, Mendelson E, Freedman LS, Kreiss Y, Lustig Y, Regev-Yochay G. Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose. N Engl J Med. 2022 Nov 9. doi: 10.1056/NEJMc2211283. Epub ahead of print. PMID: 36351266.

Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis associate
Read more

COVID in May

Image
Concerns about a potential resurgence of COVID-19 are mounting as summer 2024 approaches.  This is driven by several indicators, including social media posts, healthcare data, and wastewater surveillance across different regions. Our study findings corroborate this trend.  While many forecasters anticipate a surge, others expect a gradual increase through the end of May, and then a decline again around early June. Reports from social media suggest emerging clusters of COVID-19 in Texas, several Canadian provinces, the UK, and on cruises in northern regions such as a Norwegian cruise to Alaska.  Data from Alberta's Respiratory virus dashboard   (total weekly laboratory-confirmed COVID-19 cases) and wastewater surveillance in Calgary indicate an uptick in COVID-19 cases starting April 2024. The most recent statistics from Alberta Health reveal a significant increase in hospitalizations due to COVID-19, with 114 individuals currently hospitalized—an increase of more than 20% over two
Read more

Chronic SARS-CoV-2 Shedding

Image
Chronic viral shedding, a condition where the virus continues to be released from an individual's body long after the initial infection, has been observed in many infectious diseases, including COVID-19.  In such cases, individuals may remain asymptomatic or experience only mild symptoms while the virus persists. It remains detectable in repeated tests over an extended period and can still infect others even in nasal swab is negative (which happens quite often ). This was evident in our study.    Recent research by Conway et al. (2024) highlights the possibility of chronic SARS-CoV-2 infection, extending over several months and potentially years. Other studies have documented prolonged asymptomatic infections and extended viral shedding in moderate to severe beyond hospital discharge. Analysis of sequencing data on UK samples taken between 2 November 2020 and 15 August 2022 lead to estimates that 0.1–0.5% of infections may become persistent with typically rebounding high viral load
Read more